Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTOF), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc. (APTOF) is a clinical-stage precision oncology company focused on developing small molecule therapies for hematologic cancers, particularly acute myeloid leukemia (AML). The news flow around Aptose centers on the clinical progress of its lead oral kinase inhibitor tuspetinib (TUS), corporate financing arrangements, and a planned acquisition by Hanmi Pharmaceutical Co. Ltd.
Investors following APTOF news will see regular updates on the TUSCANY Phase 1/2 trial, where tuspetinib is combined with standard dosing of venetoclax and azacitidine (TUS+VEN+AZA) as a triple drug frontline therapy for newly diagnosed AML patients ineligible for induction chemotherapy. Company press releases highlight safety data, complete remission (CR/CRh) rates, minimal residual disease (MRD) negativity, and responses across diverse genetic subtypes, including patients with adverse mutations such as TP53, RAS, FLT3-ITD, NPM1c, and myelodysplasia-related mutations.
The Aptose news stream also includes quarterly financial results, where management discusses research and development spending by program, cash position, and reliance on loan facilities from Hanmi to fund operations. Additional items include announcements of conference presentations at major meetings such as the European Hematology Association (EHA), the European School of Haematology (ESH), and the American Society of Hematology (ASH), where new clinical data from TUSCANY are presented.
Another key category of news involves transaction and governance updates. Aptose has announced an arrangement agreement under which a Hanmi subsidiary will acquire all outstanding common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. The company also reports outcomes of shareholder meetings and changes in its independent auditor. For readers tracking APTOF, this news page provides a consolidated view of clinical, financial, and corporate developments disclosed by the company.
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, announced its upgrade to the OTCQB Market effective July 1, 2025. The company, which develops tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will maintain its listing on the Toronto Stock Exchange (TSX) under the symbol "APS".
The OTCQB Venture Market caters to early-stage and developing U.S. and international companies that meet current reporting requirements and undergo annual verification and management certification processes.
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, has reached an agreement with Hanmi Pharmaceutical to defer interest payments on their 2024 loan facility. The company, which is developing tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will have two interest payments originally due on June 27, 2025, and June 30, 2025, deferred until December 31, 2025.
The deferred payments cover interest periods from December 21, 2024, to March 31, 2025, and from March 31, 2025, to June 30, 2025, respectively.